Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy

Cancer

Volumn 116, Issue SUPPL. 4, 2010, Pages 1093-1100

  Ferrer, Ludovic ^a,b   Kraeber Bodéré, Françoise ^b,c,d   Bodet Milin, Caroline ^b,d   Rousseau, Caroline ^b,c   Le Gouill, Stephen ^b,d   Wegener, William A ^e   Goldenberg, David M ^f   Bardiès, Manuel ^a,b,c,d  

^a Medical Physics Department   (France)

^b Team 12   (France)

^c Nuclear Medicine Department   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e IMMUNOMEDICS INC   (United States)

^f CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

CD22; Epratuzumab; Radioimmunotherapy; Red marrow dosimetry; Yttrium 90

Indexed keywords

EPRATUZUMAB; INDIUM 111; YTTRIUM 90;

ADULT; BLOOD SAMPLING; BLOOD TOXICITY; BONE MARROW; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DOSIMETRY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INFUSION; ERYTHROCYTE; FEMALE; HEMATOCRIT; HUMAN; LEUKOPENIA; LYMPHOMA; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA; TOXICITY; TREATMENT DURATION;

ADOLESCENT; ADULT; BONE MARROW; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOTHERAPY DOSAGE; YTTRIUM RADIOISOTOPES;

EID: 76249091035     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24797     Document Type: Conference Paper

References (28)

1. Goldenberg DM, Sharkey RM. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging. 2006;50:248-264.
2. Chatal JF. Radioimmunotherapy, a new breakthrough in the treatment of follicular non-Hodgkin's lymphoma: the European perspective. Cancer Biother Radiopharm. 2006;21: 1-4.
3. Goldenberg DM, Horowitz JA, Sharkey RM, et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol. 1991;9:548-564.
4. Juweid M, Sharkey RM, Markowitz A, et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res. 1995;55:5899s-5907s.
5. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). Clin Cancer Res. 1999;5: 3292s-3303s.
6. 90Y-epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med. 2003;44:2000-2018.
7. 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res. 2005;11:5215-5222.
8. 90Y-DOTA-epratuzumab: An agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med. 2003;44:77-84.
9. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibodies Immunoconjugates Radioimmunopharm. 1990;3:213-233.
10. Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med. 1999;40:2102-2106.
11. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689-694.
12. Siegel JA, Yeldell D, Goldenberg DM, et al. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: Improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med. 2003;44:67-76.
13. Williams T, Kelley C. Available at: http://www.gnuplot.info. Accessed February 18, 2009.
14. Ferrer L, Carlier T, Lisbona A, Bardies M. An Image J plugin to create WB TAC using CT scanner. Eur. J Nucl Med. 2007;34(suppl):S198.
15. Seo Y, Wong KH, Sun M, Franc BL, Hawkins RA, Hasegawa BH. Correction of photon attenuation and collimator response for a body-contouring spect/ct imaging system. J Nucl Med. 2005;46:868-877.
16. Yushkevich PA, Piven J, Hazlett HC, et al. User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability. Neuroimage. 2006;31:1116-1128.
17. Ogawa K, Harata Y, Ichihara T, Kubo A, Hashimoto SA. Practical method for position-dependent compton-scatter correction in single photon emission ct. IEEE Trans Med Imaging. 1991;10:408-412.
18. Thevenaz P, Ruttimann UE, Unser MA. Pyramid approach to subpixel registration based on intensity. IEEE Trans Image Process. 1998;7:27-41.
19. Siegel JA, Lee RE, Pawlyk DA, Horowitz JA, Sharkey RM, Goldenberg DM. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Int J Rad Appl Instrum B. 1989;16:553-559.
20. Shen S, Meredith RF, Duan J, et al. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting y-antibody therapy. J Nucl Med. 2002;43:1245-1253.
21. Feller PA, Sodd VJ, Kereiakes JG. Using the S tables of MIRD Pamphlet 11. J Nucl Med. 1977;18:747.
22. Juweid M, Sharkey RM, Siegel JA, Behr T, Goldenberg DM. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake. Cancer Res. 1995;55:5827s-5831s.
23. Siegel JA. Establishing a clinically meaningful predictive model of hematologic toxicity in nonmyeloablative targeted radiotherapy: practical aspects and limitations of red marrow dosimetry. Cancer Biother Radiopharm. 2005;20:126-140.
24. Lim SM, DeNardo GL, DeNardo DA, et al. Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources. J Nucl Med. 1997;38:1374-1378.
25. DeNardo DA, DeNardo GL, O'Donnell RT, et al. Imaging for improved prediction of myelotoxicity after radioimmunotherapy. Cancer. 1997;80:2558s-2566s.
26. Meredith RF, Shen S, Forero A, LoBuglio AF. A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae. J Nucl Med. 2008;49:279-284.
27. Liu A, Williams LE, Raubitschek AA. A CT assisted method for absolute quantitation of internal radioactivity. Med Phys. 1996;23:1919-1928.
28. Wessels BW, Konijnenberg MW, Dale RG, et al. MIRD pamphlet no. 20: The effect of model assumptions on kidney dosimetry and response-implications for radionuclide therapy. J Nucl Med. 2008;49:1884-1899.